Li Gan, PhD, wants to find treatments to help patients with Alzheimer’s disease. Like most researchers, she’s hit a few major roadblocks.
When researchers like Gan find potential new drugs, it’s useful to test them on human cells to increase the chances that they will benefit patients. Historically, these tests have been conducted in cancer cells, which often don’t match the biology of human brain cells.
“The problem is that brain cells from actual people don’t survive well in a dish, so we need to engineer human cells in the lab,” explained Gan, senior investigator at the Gladstone Institutes. “But, that’s not as simple as it may sound.”
Many scientists use induced pluripotent stem cells (iPSCs) to address this issue. IPSCs are made by reprogramming skin cells or blood cells to become stem cells, which can then be transformed into any type of cell in the body. Gan uses iPSCs to produce brain cells, such as neurons or glial cells, because they are relevant to neurodegenerative disease.
Human brain cells derived from iPSCs offer great potential for drug screening. Yet, the process for producing them can be complicated, expensive, and highly variable. Many of the current methods produce cells that are heterogeneous, or different from one another, and this can lead to inconsistent results in drug screening. In addition, producing a large number of cells is very costly, so it’s difficult to scale up for big experiments.
A new platform developed in Gan’s lab will now allow scientists to overcome these constraints
A New Technique Is Born
“I came across a new method to produce iPSCs that was developed at Stanford,” said Michael Ward, MD, PhD, a former staff scientist in Gan’s lab who is now an investigator at the National Institutes of Health. “I thought that if our team could find a way to simplify and better control that approach, we might be able to improve the way we engineer human brain cells in the lab.”
Ward and his colleague Chao Wang, PhD, discovered a way to manipulate the genetic makeup of cells to produce thousands of neurons from a single iPSC. This meant that every engineered brain cell was now identical.
“I was truly motivated by our initial results,” said Gan, who is also a professor of neurology at UC San Francisco. “I had observed too much variability using the traditional methods, which made reproducing experiments quite problematic. So, the ability to produce homogeneous human brain cells was very exciting.”
The team further improved the technique to create a simplified, two-step process. This allows scientists to precisely control how many brain cells they produce and makes it easier to replicate their results from one experiment to the next.
Their technique also greatly accelerates the process. While it would normally take several months to produce brain cells, Gan and her team can now engineer large quantities of them within 1 or 2 weeks, and have functionally active neurons within 1 month.
The researchers realized this new approach had tremendous potential to screen drugs and to study disease mechanisms. To prove it, they tested it in their own research.
They applied their technique to produce human neurons by using iPSCs. Then, they developed a drug discovery platform and screened 1,280 compounds. Their goal is to identify the compounds that could lower levels of the protein tau in the brain, which is considered one of the most promising approaches in Alzheimer’s research and could potentially lead to new drugs to treat the disease.
“We showed that we can engineer large quantities of human brain cells that are all the same, while also significantly reducing the costs,” said Wang, Gladstone postdoctoral scholar. “This means our technology can easily be scaled up and can essentially be used to screen millions of compounds.”
A Powerful Tool for the Entire Scientific Community
“We have developed a cost-effective technology to produce large quantities of human brain cells in two simple steps,” summarized Gan. “By surmounting major challenges in human neuron-based drug discovery, we believe this technique will be adopted widely in both basic science and industry.”
Word of this useful new technology has already spread, and people from different scientific sectors have come knocking on Gan’s door to learn about it. Her team has shared the new method with scores of academic colleagues, some of whom had no experience with cell culture. So far, they all successfully repeated the two-step process to produce their own cells and facilitate scientific discoveries.
Details of this new technique were published on October 10, 2017, in the scientific journal Stem Cell Reports.
With some of the roadblocks out of the way, Gan hopes more discoveries will soon help the millions who suffer from Alzheimer’s disease and related conditions.
Learn more: Growing Human Brain Cells in the Lab
The Latest on: Drug discovery
[google_news title=”” keyword=”drug discovery” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
- GenScript Singapore's Open Day Reveals Pioneering AI Capabilities in Recombinant Protein Production and Drug Discoveryon April 23, 2024 at 8:01 pm
GenScript, a global leader in life sciences and biotechnology, successfully hosted an Open Day event at its Singapore facility on the 16th of April, welcoming more than 50 representatives from ...
- Transforming Drug Discovery: Birmingham Drug Discovery Hub Creates Investment-Ready ‘Drug Library’on April 23, 2024 at 4:29 am
A novel approach to drug discovery is enabling University of Birmingham researchers to overcome the ‘valley of death’, where projects fail due to the funding gap between original research and ...
- Japan’s SMBC joins JV to support drug discovery start-upson April 22, 2024 at 9:20 pm
The bank will own 33.2% of the JV company, which will be established mid-2024. Sumitomo Mitsui Banking Corporation (SMBC) has entered into an agreement with Takeda Pharmaceutical Company and Astellas ...
- AI is boosting drug discovery and development — and sparking questions about proprietary dataon April 22, 2024 at 1:47 pm
AI and Biotech panel at Life Science Innovation Northwest 2024. From left: Danielle Greenawalt, Lynda Stuart, Sean McClain, Jonathan Cohen and moderator ...
- Takeda and others sign agreement to form early drug discovery incubation JVon April 22, 2024 at 7:19 am
Takeda holds a 33.4% stake in the new company while Astellas and SMBC own 33.4% and 33.2% stakes, respectively.
- Pharmas form joint venture to jumpstart Japanese drug researchon April 22, 2024 at 7:05 am
A new initiative backed by Takeda, Astellas and Sumitomo Mitsui Banking aims to combat a decade-long decline in drug R&D productivity in Japan.
- Takeda, Astellas, Sumitomo Mitsui Banking To Form JV For Incubation Of Early Drug Discovery Programson April 22, 2024 at 2:25 am
The new JV will be for the incubation of early drug discovery programs, primarily originating from Japan and toward the creation of innovative therapeutics. The JV is expected to be established in mid ...
- Lecture held on drug discovery and career opportunities in pharmaceutical industryon April 21, 2024 at 4:28 am
The Department of Pharmacology, J.N. Medical College, Aligarh Muslim University organized a lecture on “Drug Discovery and Career Opportunities in Pharmaceutical Industry” by Dr. Syed Mubarak Naqvi, a ...
- ELRIG UK and SRG announce partnership to advance life science professionals in drug discoveryon April 17, 2024 at 2:54 am
UK, a not-for-profit, volunteer-led organization for the drug discovery community, today entered into a partnership with SRG, leaders in life science recruitment, to support the advancement of science ...
- Why AI holds the key to accelerating the drug discovery processon April 16, 2024 at 9:00 pm
Insilico is calling its achievement a “milestone” for generative AI in drug development, and says the latest paper functions as a blueprint for an industry undergoing a paradigm shift. Indeed, a ...
via Google News and Bing News